These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 26122843)

  • 61. Analysis of chemotherapeutic response in ovarian cancers using publicly available high-throughput data.
    Bosquet JG; Marchion DC; Chon H; Lancaster JM; Chanock S
    Cancer Res; 2014 Jul; 74(14):3902-12. PubMed ID: 24848511
    [TBL] [Abstract][Full Text] [Related]  

  • 62. An integrated model of clinical information and gene expression for prediction of survival in ovarian cancer patients.
    Yang R; Xiong J; Deng D; Wang Y; Liu H; Jiang G; Peng Y; Peng X; Zeng X
    Transl Res; 2016 Jun; 172():84-95.e11. PubMed ID: 27059002
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Large-scale integrated analysis of ovarian cancer tumors and cell lines identifies an individualized gene expression signature for predicting response to platinum-based chemotherapy.
    Sun J; Bao S; Xu D; Zhang Y; Su J; Liu J; Hao D; Zhou M
    Cell Death Dis; 2019 Sep; 10(9):661. PubMed ID: 31506427
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Unsupervised analysis reveals two molecular subgroups of serous ovarian cancer with distinct gene expression profiles and survival.
    Lisowska KM; Olbryt M; Student S; Kujawa KA; Cortez AJ; Simek K; Dansonka-Mieszkowska A; Rzepecka IK; Tudrej P; Kupryjańczyk J
    J Cancer Res Clin Oncol; 2016 Jun; 142(6):1239-52. PubMed ID: 27028324
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Cumulative genetic risk predicts platinum/taxane-induced neurotoxicity.
    McWhinney-Glass S; Winham SJ; Hertz DL; Yen Revollo J; Paul J; He Y; Brown R; Motsinger-Reif AA; McLeod HL;
    Clin Cancer Res; 2013 Oct; 19(20):5769-76. PubMed ID: 23963862
    [TBL] [Abstract][Full Text] [Related]  

  • 66. DNA methylation of the immediate upstream region of BRCA1 major transcription start sites is an independent favorable prognostic factor in patients with high-grade serous ovarian cancer.
    Ebata T; Yamashita S; Takeshima H; Yoshida H; Kawata Y; Kino N; Yasugi T; Terao Y; Yonemori K; Kato T; Ushijima T
    Gynecol Oncol; 2022 Dec; 167(3):513-518. PubMed ID: 36253303
    [TBL] [Abstract][Full Text] [Related]  

  • 67. DNA methylation profiles in ovarian cancer: implication in diagnosis and therapy (Review).
    Koukoura O; Spandidos DA; Daponte A; Sifakis S
    Mol Med Rep; 2014 Jul; 10(1):3-9. PubMed ID: 24821107
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Association between targeted somatic mutation (TSM) signatures and HGS-OvCa progression.
    Lindley RA; Humbert P; Larner C; Akmeemana EH; Pendlebury CR
    Cancer Med; 2016 Sep; 5(9):2629-40. PubMed ID: 27485054
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Virtual clinical trials identify effective combination therapies in ovarian cancer.
    Kozłowska E; Vallius T; Hynninen J; Hietanen S; Färkkilä A; Hautaniemi S
    Sci Rep; 2019 Dec; 9(1):18678. PubMed ID: 31822719
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Acquisition of taxane resistance by p53 inactivation in ovarian cancer cells.
    Shu C; Zheng X; Wuhafu A; Cicka D; Doyle S; Niu Q; Fan D; Qian K; Ivanov AA; Du Y; Mo X; Fu H
    Acta Pharmacol Sin; 2022 Sep; 43(9):2419-2428. PubMed ID: 35031699
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Big data and computational biology strategy for personalized prognosis.
    Ow GS; Tang Z; Kuznetsov VA
    Oncotarget; 2016 Jun; 7(26):40200-40220. PubMed ID: 27229533
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Comprehensive analysis of mRNA-level and miRNA-level subpathway activities for identifying robust ovarian cancer prognostic signatures.
    Tian S; Mi W; Zhang M; Xing L; Zhang C
    J Cell Mol Med; 2020 Feb; 24(4):2582-2592. PubMed ID: 31957240
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Investigation of selective glucocorticoid receptor modulation in high-grade serous ovarian cancer PDX models.
    Taya M; Hou X; Veneris JT; Kazi N; Larson MC; Maurer MJ; Heinzen EP; Chen H; Lastra R; Oberg AL; Weroha SJ; Fleming GF; Conzen SD
    J Gynecol Oncol; 2024 Jun; ():. PubMed ID: 38909640
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Epigenetic loss of heparan sulfate 3-O-sulfation sensitizes ovarian carcinoma to oncogenic signals and predicts prognosis.
    Huang RL; Chen HJ; Chen LY; Chao TK; Lin WY; Liew PL; Su PH; Weng YC; Wang YC; Liao CC; Hsu YW; Wang HC; Lai HC
    Int J Cancer; 2018 Oct; 143(8):1943-1953. PubMed ID: 29732534
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Systematic transcriptome analysis reveals tumor-specific isoforms for ovarian cancer diagnosis and therapy.
    Barrett CL; DeBoever C; Jepsen K; Saenz CC; Carson DA; Frazer KA
    Proc Natl Acad Sci U S A; 2015 Jun; 112(23):E3050-7. PubMed ID: 26015570
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Multiple signatures of a disease in potential biomarker space: Getting the signatures consensus and identification of novel biomarkers.
    Ow GS; Kuznetsov VA
    BMC Genomics; 2015; 16 Suppl 7(Suppl 7):S2. PubMed ID: 26100469
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Deciphering serous ovarian carcinoma histopathology and platinum response by convolutional neural networks.
    Yu KH; Hu V; Wang F; Matulonis UA; Mutter GL; Golden JA; Kohane IS
    BMC Med; 2020 Aug; 18(1):236. PubMed ID: 32807164
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Ovarian cancer: Novel molecular aspects for clinical assessment.
    Palmirotta R; Silvestris E; D'Oronzo S; Cardascia A; Silvestris F
    Crit Rev Oncol Hematol; 2017 Sep; 117():12-29. PubMed ID: 28807232
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A multiomics comparison between endometrial cancer and serous ovarian cancer.
    Zhong H; Chen H; Qiu H; Huang C; Wu Z
    PeerJ; 2020; 8():e8347. PubMed ID: 31942259
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Clinical importance of the EMSY gene expression and polymorphisms in ovarian cancer.
    Dansonka-Mieszkowska A; Szafron LM; Moes-Sosnowska J; Kulinczak M; Balcerak A; Konopka B; Kulesza M; Budzilowska A; Lukasik M; Piekarska U; Rzepecka IK; Parada J; Zub R; Pienkowska-Grela B; Madry R; Siwicki JK; Kupryjanczyk J
    Oncotarget; 2018 Apr; 9(25):17735-17755. PubMed ID: 29707144
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.